Biology Reference
In-Depth Information
247. Bai AH, Tong JH, To KF, et al. Promoter hypermethylation of
tumor-related genes in the progression of colorectal neoplasia.
Int
J Cancer
2004;
112
:846
e
53.
248. Lee MN, Tseng RC, Hsu HS, et al. Epigenetic inactivation of the
chromosomal stability control genes BRCA1, BRCA2, XRCC5 in
non-small cell lung cancer.
Clin Cancer Res
2007;
13
:832
e
8.
249. Leng S, Stidley CA, Willink R, et al. Double-strand break damage
and associated DNA repair genes predispose smokers to gene
methylation.
Cancer Res
2008;
68
:3049
e
56.
250. Bartel DP. MicroRNAs: target recognition and regulatory func-
tions.
Cell
2009;
136
:215
e
33.
251. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian
mRNAs are conserved targets of microRNAs.
Genome Res
2009;
19
:92
e
105.
252. Valeri N, Gasparini P, Fabbri M, et al. Modulation of mismatch
repair and genomic stability by miR-155.
Proc Natl Acad Sci USA
2010;
107
:6982
e
7.
253. Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA. ATM is down-
regulated by N-Myc-regulated microRNA-421.
Proc Natl Acad Sci
USA
2010;
107
:1506
e
11.
254. Yan D, Ng WL, Zhang X, et al. Targeting DNA-PKcs and ATM
with miR-101 sensitizes tumors to radiation.
PLoS One
2010;
5
:e11397.
255. Choudhury A, Nelson LD, Teo MT, et al. MRE11 expression is
predictive of cause-specific survival following radical radio-
therapy for muscle-invasive bladder cancer.
Cancer Res
2010;
70
:
7017
e
26.
256. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations
and survival in chronic lymphocytic leukemia.
N Engl J Med
2000;
343
:1910
e
6.
257. Soderlund K, Stal O, Skoog L, Rutqvist LE, Nordenskjold B,
Askmalm MS. Intact Mre11/Rad50/Nbs1 complex predicts good
response to radiotherapy in early breast cancer.
Int J Radiat Oncol
Biol Phys
2007;
68
:50
e
8.
258. Pavon MA, Parreno M, Leon X, et al. Ku70 predicts response and
primary tumor recurrence after therapy in locally advanced head
and neck cancer.
Int J Cancer
2008;
123
:1068
e
79.
259. Yang CR, Leskov K, Hosley-Eberlein K, et al. Nuclear clusterin/
XIP8, an x-ray-induced Ku70-binding protein that signals cell
death.
Proc Natl Acad Sci USA
2000;
97
:5907
e
12.
260. Ho AY, Fan G, Atencio DP, et al. Possession of ATM sequence
variants as predictor for late normal tissue responses in breast
cancer patients treated with radiotherapy.
Int J Radiat Oncol Biol
Phys
2007;
69
:677
e
84.
261. Edvardsen H, Tefre T, Jansen L, et al. Linkage disequilibrium
pattern of the ATM gene in breast cancer patients and controls;
association of SNPs and haplotypes to radio-sensitivity and post-
lumpectomy local recurrence.
Radiat Oncol
2007;
2
:25.
262. Damaraju S, Murray D, Dufour J, et al. Association of DNA repair
and steroid metabolism gene polymorphisms with clinical late
toxicity in patients treated with conformal radiotherapy for
prostate cancer.
Clin Cancer Res
2006;
12
:2545
e
54.
263. Pugh TJ, Keyes M, Barclay L, et al. Sequence variant discovery in
DNA repair genes from radiosensitive and radiotolerant prostate
brachytherapy patients.
Clin Cancer Res
2009;
15
:5008
e
16.
264. Werbrouck J, De Ruyck K, Duprez F, et al. Acute normal tissue
reactions in head-and-neck cancer patients treated with IMRT:
influence of dose and association with genetic polymorphisms in
DNA DSB repair genes.
Int J Radiat Oncol Biol Phys
2009;
73
:
1187
e
95.
265. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, et al. Wortmannin
inactivates phosphoinositide 3-kinase by covalent modification of
Lys-802, a residue involved in the phosphate transfer reaction.
Mol Cell Biol
1996;
16
:1722
e
33.
266. Block WD, Merkle D, Meek K, Lees-Miller SP. Selective inhibition
of the DNA-dependent protein kinase (DNA-PK) by the radio-
sensitizing agent caffeine.
Nucleic Acids Res
2004;
32
:1967
e
72.
267. Leahy JJ, Golding BT, Griffin RJ, et al. Identification of a highly
potent and selective DNA-dependent protein kinase (DNA-PK)
inhibitor (NU7441) by screening of chromenone libraries.
Bioorg
Med Chem Lett
2004;
14
:6083
e
7.
268. Hardcastle IR, Cockcroft X, Curtin NJ, et al. Discovery of potent
chromen-4-one inhibitors of the DNA-dependent protein kinase
(DNA-PK) using a small-molecule library approach.
J Med Chem
2005;
48
:7829
e
46.
269. Hickson I, Zhao Y, Richardson CJ, et al. Identification and char-
acterization of a novel and specific inhibitor of the ataxia-
telangiectasia mutated kinase ATM.
Cancer Res
2004;
64
:9152
e
9.
270. Rainey MD, Charlton ME, Stanton RV, Kastan MB. Transient
inhibition of ATM kinase is sufficient to enhance cellular sensi-
tivity to ionizing radiation.
Cancer Res
2008;
68
:7466
e
74.
271. Durant S, Karran P. Vanillins
e
a novel family of DNA-PK
inhibitors.
Nucleic Acids Res
2003;
31
:5501
e
12.
272. Elliott SL, Crawford C, Mulligan E, et al. Mitoxantrone in
combination with an inhibitor of DNA-dependent protein kinase:
a potential therapy for high risk B-cell chronic lymphocytic
leukaemia.
Br J Haematol
2011;
152
:61
e
71.
273. Chen X, Zhong S, Zhu X, et al. Rational design of human DNA
ligase inhibitors that target cellular DNA replication and repair.
Cancer Res
2008;
68
:3169
e
77.
274. Rasouli-Nia A, Karimi-Busheri F, Weinfeld M. Stable down-
regulation of human polynucleotide kinase enhances sponta-
neous mutation frequency and sensitizes cells to genotoxic
agents.
Proc Natl Acad Sci USA
2004;
101
:6905
e
10.
275. Freschauf GK, Karimi-Busheri F, Ulaczyk-Lesanko A, et al.
Identification of a small molecule inhibitor of the human DNA
repair enzyme polynucleotide kinase/phosphatase.
Cancer Res
2009;
69
:7739
e
46.
276. Freschauf GK, Mani RS, Mereniuk TR, et al. Mechanism of action
of an imidopiperidine inhibitor of human polynucleotide kinase/
phosphatase.
J Biol Chem
2010;
285
:2351
e
60.
277. Jones KR, Gewirtz DA, Yannone SM, et al. Radiosensitization of
MDA-MB-231 breast tumor cells by adenovirus-mediated over-
expression of a fragment of the XRCC4 protein.
Mol Cancer Ther
2005;
4
:1541
e
7.
278. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-
induced EGFR nuclear import by C225 (Cetuximab) suppresses
DNA-PK activity.
Radiother Oncol
2005;
76
:157
e
61.
279. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of
BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)
polymerase.
Nature
2005;
434
:913
e
7.
280. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair
defect in BRCA mutant cells as a therapeutic strategy.
Nature
2005;
434
:917
e
21.
281. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-
ribose) polymerase inhibitor olaparib in patients with BRCA1 or
BRCA2 mutations and recurrent ovarian cancer: a proof-of-
concept trial.
Lancet
2010;
376
:245
e
51.
282. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose)
polymerase in tumors from BRCA mutation carriers.
N Engl J
Med
2009;
361
:123
e
34.
283. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) poly-
merase inhibitor olaparib in patients with BRCA1 or BRCA2
mutations and advanced breast cancer: a proof-of-concept trial.
Lancet
2010;
376
:235
e
44.
284. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP)
ribose polymerase inhibitors for the treatment of cancers deficient
in DNA double-strand break repair.
J Clin Oncol
2008;
26
:3785
e
90.
